Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS).
combination therapy
daptomycin
endocarditis
gram-positive
survey
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
02 Jan 2022
02 Jan 2022
Historique:
received:
16
10
2021
revised:
26
12
2021
accepted:
28
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
infective endocarditis (IE) remains a severe disease frequently encountered in clinical practice and often requiring interdisciplinary medical and surgical management. This national survey aims to describe the clinical prescribing habits of the use of daptomycin in the setting of IE and the possible role for combination therapy with beta-lactams. The study was a cross-sectional internet-based questionnaire survey on therapy with daptomycin. The questionnaire was designed with closed-ended questions and distributed using the SurveyMonkey 55 clinicians from twelve Italians regions joined the questionnaire. The survey reported use of daptomycin as first-line choice in 31.48% of cases and as the first-line anti-MRSA agent in 44.44%. The empiric use of daptomycin was stated in the high suspicion of MRSA rather than MSSA, enterococcal or streptococcal IE. The rationale of daptomycin for the empirical treatment of native and prosthetic valve IE was mostly the possibility of administering an aminoglycoside-sparing combination regimen, high bacterial killing rate and high clinical efficacy. In conclusion, in selected patients, daptomycin could be a feasible option for the treatment of infective endocarditis in line with data from the European registry of daptomycin.
Sections du résumé
BACKGROUND
BACKGROUND
infective endocarditis (IE) remains a severe disease frequently encountered in clinical practice and often requiring interdisciplinary medical and surgical management. This national survey aims to describe the clinical prescribing habits of the use of daptomycin in the setting of IE and the possible role for combination therapy with beta-lactams.
METHODS
METHODS
The study was a cross-sectional internet-based questionnaire survey on therapy with daptomycin. The questionnaire was designed with closed-ended questions and distributed using the SurveyMonkey
RESULTS
RESULTS
55 clinicians from twelve Italians regions joined the questionnaire. The survey reported use of daptomycin as first-line choice in 31.48% of cases and as the first-line anti-MRSA agent in 44.44%. The empiric use of daptomycin was stated in the high suspicion of MRSA rather than MSSA, enterococcal or streptococcal IE. The rationale of daptomycin for the empirical treatment of native and prosthetic valve IE was mostly the possibility of administering an aminoglycoside-sparing combination regimen, high bacterial killing rate and high clinical efficacy.
CONCLUSIONS
CONCLUSIONS
In conclusion, in selected patients, daptomycin could be a feasible option for the treatment of infective endocarditis in line with data from the European registry of daptomycin.
Identifiants
pubmed: 35052933
pii: antibiotics11010056
doi: 10.3390/antibiotics11010056
pmc: PMC8773184
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2013 Dec;57(12):6213-22
pubmed: 24080644
Clin Infect Dis. 2018 Aug 16;67(5):795-798
pubmed: 29659732
J Antimicrob Chemother. 2014 Feb;69(2):568-71
pubmed: 24107389
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
JAMA. 2020 Feb 11;323(6):527-537
pubmed: 32044943
Arch Intern Med. 2009 Jul 27;169(14):1290-8
pubmed: 19636030
Antimicrob Agents Chemother. 2012 Feb;56(2):838-44
pubmed: 22123698
Int J Antimicrob Agents. 2013 May;41(5):468-72
pubmed: 23473943
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):202-207
pubmed: 30957862
Eur Heart J. 2019 Oct 14;40(39):3222-3232
pubmed: 31504413
Diagn Microbiol Infect Dis. 2019 Feb;93(2):131-135
pubmed: 30279024
Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30
pubmed: 31629409
J Thorac Cardiovasc Surg. 2017 Jun;153(6):1241-1258.e29
pubmed: 28365016
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32312776
Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):111-8
pubmed: 26563898
N Engl J Med. 2019 Apr 4;380(14):1373-1374
pubmed: 30883059
Clin Infect Dis. 2018 Jul 2;67(2):303-309
pubmed: 29390132
J Antimicrob Chemother. 2008 Dec;62(6):1413-21
pubmed: 18782781
J Antimicrob Chemother. 2013 Apr;68(4):936-42
pubmed: 23190763
J Cardiovasc Med (Hagerstown). 2008 May;9(5):508-14
pubmed: 18404005
Curr Infect Dis Rep. 2014 Oct;16(10):429
pubmed: 25165017
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858203
N Engl J Med. 2019 Jan 31;380(5):415-424
pubmed: 30152252
Clin Microbiol Rev. 2013 Oct;26(4):759-80
pubmed: 24092854
N Engl J Med. 2006 Aug 17;355(7):653-65
pubmed: 16914701
Pharmacotherapy. 2020 Jul;40(7):648-658
pubmed: 32533859
Clin Infect Dis. 2013 Jun;56(11):1562-9
pubmed: 23449272
Open Forum Infect Dis. 2019 Dec 31;7(1):ofz538
pubmed: 31938716
Am J Cardiol. 2013 Oct 15;112(8):1171-6
pubmed: 23831163
Clin Infect Dis. 2020 Jun 24;71(1):1-10
pubmed: 31404468
J Mol Med (Berl). 2014 Feb;92(2):139-49
pubmed: 24297496